


IN THE CLAIMS:

Claims 1-10 (cancel without prejudice).

Claim 11 (currently amended): A method of treating cancer selected from the group consisting of lung, liver, brain, pancreatic, kidney, prostate, breast, colon and head-neck cancers comprising administering to a warm-blooded animal including humans afflicted with said cancer a cancer-treating effective amount of the a pharmaceutical composition of claim 1 comprising at least one prostacyclin derivative selected from compounds of Formula I and pharmaceutically acceptable salts and esters thereof



wherein:

n is 0 or 1;

X is selected from O or NH;

R₁ is selected from the group consisting of O, N, S and C;

R₂ is an alkyl group having at least one carbon atom, and

R is selected from H or an alkyl group having at least one carbon atom, and a pharmaceutically acceptable carrier.

Claim 12 (original): The method of claim 11 comprising administering said at least one prostacyclin derivative in a dosage amount of from about 0.01 µg/kg/day to 500 mg/kg/day to said warm-blooded animal.

Claim 13 (original): The method of claim 11 comprising administering said at least one prostacyclin derivative in a dosage amount of from about 0.01 µg/kg/day to 100 mg/kg/day to said warm-blooded animal.


Claim 14 (original): The method of claim 11 comprising administering said pharmaceutical composition intravenously to said warm-blooded animal.

Claim 15 (original): The method of claim 11 comprising administering said pharmaceutical composition subcutaneously to said warm-blooded animal.

Claim 16 (original): The method of claim 11 comprising administering said pharmaceutical composition by inhalation to said warm-blooded animal.

Claim 17 (original): The method of claim 11 comprising administering said pharmaceutical composition orally to said warm-blooded animal.

Claim 18 (currently amended): A method of inhibiting metastasis in a warm-blooded animal including humans afflicted with a cancer selected from the group consisting of lung, liver, brain, pancreatic, kidney, prostate, breast, colon and head-neck cancers, said method comprising administering to the warm-blooded animal a metastasis-inhibiting effective amount of the a pharmaceutical composition of claim 5 comprising at least one prostacyclin derivative selected from compounds of Formula I and pharmaceutically acceptable salts and esters thereof



wherein:

n is 0 or 1;


X is selected from O or NH;

R₁ is selected from the group consisting of O, N, S and C;

R₂ is an alkyl group having at least one carbon atom, and

R is selected from H or an alkyl group having at least one carbon atom, and a pharmaceutically acceptable carrier.

Claim 19 (currently amended): A method of inhibiting protein degradation caused by cancer cells in a warm-blooded animal including humans afflicted with cancer selected from the group consisting of lung, liver, brain, pancreatic, kidney, prostate, breast, colon and head-neck cancers, said method comprising administering to the warm-blooded animal a protein degradation-inhibiting effective amount of ~~the a~~ pharmaceutical composition of claim 6 comprising at least one prostacyclin derivative selected from compounds of Formula I and pharmaceutically acceptable salts and esters thereof



wherein:

n is 0 or 1;

X is selected from O or NH;


R₁ is selected from the group consisting of O, N, S and C;

R₂ is an alkyl group having at least one carbon atom, and

R is selected from H or an alkyl group having at least one carbon atom, and a pharmaceutically acceptable carrier.

Claim 20 (currently amended): A method of promoting apoptosis in cancer cells in a warm-blooded animal including humans afflicted with cancer selected from the group consisting of lung, liver, brain, pancreatic, kidney, prostate, breast, colon and head-neck cancers, said method comprising administering to the warm-blooded animal an apoptosis-promoting effective amount of the a pharmaceutical composition

ef-claim 9 comprising at least one prostacyclin derivative selected from compounds of Formula I and pharmaceutically acceptable salts and esters thereof



wherein:

n is 0 or 1;


X is selected from O or NH;

R₁ is selected from the group consisting of O, N, S and C;

R₂ is an alkyl group having at least one carbon atom, and

R is selected from H or an alkyl group having at least one carbon atom, and a pharmaceutically acceptable carrier.

Claim 21 (currently amended): A method of controlling cell proliferation of cancer cells in a warm-blooded animal including humans afflicted with cancer selected from the group consisting of lung, liver, brain, pancreatic, kidney, prostate, breast, colon and head-neck cancers, said method comprising administering to the warm-blooded animal an antiproliferative effective amount of ~~the~~ a pharmaceutical ~~composition of claim 10 comprising at least one prostacyclin derivative selected from compounds of Formula I and pharmaceutically acceptable salts and esters thereof~~



wherein:

n is 0 or 1;

X is selected from O or NH;

R₁ is selected from the group consisting of O, N, S and C;

ARK:jsg031004\7321010.AMD

R₂ is an alkyl group having at least one carbon atom, and

R is selected from H or an alkyl group having at least one carbon atom, and a
pharmaceutically acceptable carrier.

Claims 22-28 (cancel without prejudice).